Seeking Alpha

jjjorgen

jjjorgen
Send Message
View as an RSS Feed
View jjjorgen's Comments BY TICKER:
Latest  |  Highest rated
  • Athersys, Inc: The Facts [View article]
    Great article, Bio!! Have a wonderful week!
    Apr 21 11:48 AM | 1 Like Like |Link to Comment
  • XenoPort: A High Probablity Run-Up Trade [View article]
    Great research, and informative! I own Xenoport, and your research added greatly to what I already knew on the company. Looking for positive Phase III data in May, and hope for a spike into the $9's.
    Thanks again!!
    Apr 18 09:48 AM | Likes Like |Link to Comment
  • Athersys: Valuation [View article]
    Superb article and analysis!! I've read most of the referred articles, but never put the puzzle together. Thanks so much for your hard work, and I look forward to a prosperous year in Athersys!
    Apr 12 10:32 AM | Likes Like |Link to Comment
  • Athersys, Inc. Has Blockbuster Potential [View article]
    Bio~ Thanks for the great article!! Very informative. Even with all the due diligence I've done on this one, I fee I learned a great deal. I appreciate your research here! MultiStem is very exciting!
    Mar 27 10:21 PM | Likes Like |Link to Comment
  • Spectrum Pharmaceuticals (SPPI) guides FY13 revenue below Street estimates, now anticipating total revenues in the range of $160M to $180M. Analysts were projecting FY13 revenue to come in at $297M. The company cites a change in ordering patterns of Fusilev and an increase in generic competition in its hospital segment for the shortfall, following the recent stabilization of the folate analog market. Shares remain halted AH. [View news story]
    No. Not unless this drops to $5/share, and other drugs in their pipeline begin to produce.
    Mar 12 09:36 PM | Likes Like |Link to Comment
  • A Quick Look At 8 Biotechs Ready To Gain Momentum [View article]
    You can scratch SPPI off your list!

    Spectrum Pharmaceuticals (SPPI) guides FY13 revenue below Street estimates, now anticipating total revenues in the range of $160M to $180M. Analysts were projecting FY13 revenue to come in at $297M
    Mar 12 05:00 PM | 1 Like Like |Link to Comment
  • Spectrum Pharmaceuticals (SPPI) guides FY13 revenue below Street estimates, now anticipating total revenues in the range of $160M to $180M. Analysts were projecting FY13 revenue to come in at $297M. The company cites a change in ordering patterns of Fusilev and an increase in generic competition in its hospital segment for the shortfall, following the recent stabilization of the folate analog market. Shares remain halted AH. [View news story]
    Feurestein will have a hay day with this!
    Mar 12 04:49 PM | Likes Like |Link to Comment
  • 4 Undervalued Stocks: We Like These In An Overbought Stock Market [View article]
    As far as AAPL, how low will this go??? I am long 600 shares, and this is really starting to eat at me!
    Mar 4 08:35 PM | Likes Like |Link to Comment
  • Where's The Economic Growth? [View article]
    Honestly, the market is overbought in my opinion. I've sold most equities, and I'm planning on an overdue 10% market correction. This may start now, or it may start in April. But it is coming, mark my words.
    Feb 15 07:06 PM | 3 Likes Like |Link to Comment
  • 3 Long Buys You Will Never Regret - Part 2 [View article]
    Heli, hold some money to buy AAPL again at $435. It'll be here soon.
    Feb 15 06:17 PM | 2 Likes Like |Link to Comment
  • Athersys: The Coming Year Will Define MultiStem, Its Adult Stem Cell Product [View article]
    Great article, Larry. Wish I could write like this!
    Feb 8 05:33 PM | Likes Like |Link to Comment
  • The Future Of Zalicus In 2013 [View article]
    Hold your cursor over his picture above and read what it says. He's done.
    Feb 4 10:26 AM | Likes Like |Link to Comment
  • Threshold Pharmaceuticals Announces Initiation of TH-302 Phase 3 MAESTRO Study in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma [View article]
    Have patience, but if it'll be a year without more news, I could put my money to work somewhere else, and come back to this in a year. Anything else coming up in the next few months?
    Jan 29 07:54 PM | Likes Like |Link to Comment
  • Threshold Pharmaceuticals Announces Initiation of TH-302 Phase 3 MAESTRO Study in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma [View article]
    Trying to hold to THLD, NOT liking price action. Mad at myself for not selling last week @ $5.50/shr. What gives, folks?
    Jan 29 04:55 PM | Likes Like |Link to Comment
  • Athersys: An Undervalued Spec Company With High Potential [View article]
    ZZ,
    Athersys is a risk, period. But it is a calculated risk. I'm investing in the potential of MultiStem's future. If it doesn't pan out, I move on. But right here and now, I love the potential of the science. If you invest in Biotechnology, you are a risk taker. If you don't like the risk, stick with researching and investing in Pfizer. That's your safer bet. Traders in Biotechnology love the opportunity to potentially invest in a 10 bagger.
    Good luck to you.
    Jan 21 10:10 AM | 1 Like Like |Link to Comment
COMMENTS STATS
306 Comments
198 Likes